Scott H Kaufmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4741628/publications.pdf

Version: 2024-02-01

336 papers	28,461 citations	5569 82 h-index	6128 159 g-index
434 all docs	434 docs citations	434 times ranked	29223 citing authors

#	Article	IF	Citations
1	Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis. Annual Review of Biochemistry, 1999, 68, 383-424.	5.0	2,499
2	PARP inhibition: PARP1 and beyond. Nature Reviews Cancer, 2010, 10, 293-301.	12.8	1,166
3	Induction of Apoptosis by Cancer Chemotherapy. Experimental Cell Research, 2000, 256, 42-49.	1.2	1,101
4	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	5.1	975
5	Cathepsin B contributes to TNF-Î±â€“mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. Journal of Clinical Investigation, 2000, 106, 1127-1137.	3.9	635
6	Programmed cell death: alive and well in the new millennium. Trends in Cell Biology, 2001, 11, 526-534.	3.6	603
7	The Current Status of Camptothecin Analogues as Antitumor Agents. Journal of the National Cancer Institute, 1993, 85, 271-291.	3.0	574
8	The role of proteases during apoptosis. FASEB Journal, 1996, 10, 587-597.	0.2	538
9	Caspases and caspase inhibitors. Trends in Biochemical Sciences, 1997, 22, 388-393.	3.7	517
10	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	0.8	509
11	Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. Journal of Clinical Investigation, 1999, 103, 137-145.	3.9	485
12	Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3406-3411.	3.3	475
13	Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 2001, 97, 3361-3369.	0.6	445
14	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	7.7	310
15	Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. Journal of Clinical Oncology, 2015, 33, 1397-1406.	0.8	295
16	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	7.7	278
17	Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Experimental Cell Research, 1981, 132, 105-123.	1.2	270
18	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood, 1998, 91, 991-1000.	0.6	265

#	Article	IF	Citations
19	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood, 1998, 91, 991-1000.	0.6	263
20	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005, 24, 6861-6869.	2.6	254
21	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 2003, 22, 7414-7430.	2.6	253
22	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. Blood, 1997, 90, 935-943.	0.6	247
23	Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 195-211.	2.4	239
24	Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ. Journal of Biological Chemistry, 2002, 277, 44236-44243.	1.6	239
25	Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO Journal, 2002, 21, 1967-1977.	3.5	233
26	Lowâ€dose, singleâ€agent temsirolimus for relapsed mantle cell lymphoma. Cancer, 2008, 113, 508-514.	2.0	220
27	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. Journal of Biological Chemistry, 2003, 278, 23107-23117.	1.6	215
28	Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells. Cancer Research, 2004, 64, 3517-3524.	0.4	204
29	Interleukin-6 Contributes to Mcl-1 Up-regulation and TRAIL Resistance via an Akt-Signaling Pathway in Cholangiocarcinoma Cells. Gastroenterology, 2005, 128, 2054-2065.	0.6	204
30	Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro. Clinical Cancer Research, 2012, 18, 1655-1662.	3.2	204
31	Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 1760-1766.	0.8	200
32	COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Molecular Biology of the Cell, 2015, 26, 91-103.	0.9	200
33	Activation of Multiple Interleukin-1Î² Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis. Journal of Biological Chemistry, 1997, 272, 7421-7430.	1.6	197
34	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	5.8	192
35	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	5.1	191
36	Apoptosis in cancer: cause and cure. BioEssays, 2000, 22, 1007-1017.	1.2	181

#	Article	IF	Citations
37	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, 109, 1387-1394.	0.6	180
38	S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function. Journal of Biological Chemistry, 2002, 277, 1599-1606.	1.6	179
39	Severe Graft-versus-Host Disease in a Liver-Transplant Recipient. New England Journal of Medicine, 1988, 318, 689-691.	13.9	174
40	G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. Journal of Clinical Investigation, 2002, 110, 91-99.	3.9	173
41	The erasable Western blot. Analytical Biochemistry, 1987, 161, 89-95.	1.1	172
42	Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1288-1297.	3.2	168
43	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology, 2002, 122, 985-993.	0.6	166
44	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004, 103, 3271-3277.	0.6	163
45	ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status. Cancer Research, 2013, 73, 3683-3691.	0.4	160
46	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene, 2004, 23, 1636-1644.	2.6	157
47	Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines. Journal of the National Cancer Institute, 1996, 88, 734-741.	3.0	153
48	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. Cancer Research, 2013, 73, 7222-7231.	0.4	153
49	A subset of non-histone nuclear proteins reversibly stabilized by the sulfhydryl cross-linking reagent tetrathionate. Experimental Cell Research, 1984, 155, 477-495.	1.2	152
50	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood, 2009, 114, 2926-2935.	0.6	152
51	Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. Journal of Cell Biology, 2011, 194, 39-48.	2.3	139
52	Successful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads. Journal of Medicinal Chemistry, 2000, 43, 401-408.	2.9	130
53	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. Journal of Clinical Investigation, 2006, 116, 1994-2004.	3.9	130
54	Chemotherapy-Induced Apoptosis. Advances in Pharmacology, 1997, 41, 461-499.	1.2	126

#	Article	IF	Citations
55	Transition from Caspase-dependent to Caspase-independent Mechanisms at the Onset of Apoptotic Execution. Journal of Cell Biology, 1998, 143, 225-239.	2.3	122
56	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1658-1671.	1.9	122
57	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. Blood, 1997, 90, 4283-4296.	0.6	119
58	Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival. Molecular Pharmacology, 2005, 68, 1636-1644.	1.0	119
59	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 2005, 106, 318-327.	0.6	118
60	Molecular correlates of platinum response in human highâ€grade serous ovarian cancer patientâ€derived xenografts. Molecular Oncology, 2014, 8, 656-668.	2.1	117
61	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	5.8	116
62	Caspases 3 and 9 Send a Pro-Apoptotic Signal from Synapse to Cell Body in Olfactory Receptor Neurons. Journal of Neuroscience, 2001, 21, 7099-7109.	1.7	114
63	Tumor Necrosis Factor-related Apoptosis-inducing Ligand Activates a Lysosomal Pathway of Apoptosis That Is Regulated by Bcl-2 Proteins. Journal of Biological Chemistry, 2007, 282, 28960-28970.	1.6	113
64	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
65	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015, 125, 658-667.	0.6	108
66	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 2002, 99, 664-671.	0.6	107
67	Death Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2011, 286, 39336-39348.	1.6	106
68	Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma, 2001, 110, 65-74.	1.0	104
69	MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis. Journal of Biological Chemistry, 2007, 282, 29831-29846.	1.6	104
70	The relationship of the nuclear matrix to cellular structure and function. Advances in Enzyme Regulation, 1979, 17, 213-248.	2.9	103
71	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 2006, 5, 2378-2387.	1.9	102
72	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clinical Cancer Research, 2012, 18, 6723-6731.	3.2	100

#	Article	IF	Citations
73	Retention of the Human Rad9 Checkpoint Complex in Extraction-resistant Nuclear Complexes after DNA Damage. Journal of Biological Chemistry, 2000, 275, 26343-26348.	1.6	99
74	Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia. Journal of Biological Chemistry, 2002, 277, 33968-33977.	1.6	96
75	The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Frontiers in Oncology, 2013, 3, 228.	1.3	95
76	A cell cycle-dependent BRCA1â€“UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nature Communications, 2016, 7, 10201.	5.8	95
77	Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis. Journal of Biological Chemistry, 1999, 274, 4335-4340.	1.6	94
78	Serine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1. Journal of Biological Chemistry, 2007, 282, 18407-18417.	1.6	94
79	Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology, 2001, 13, 470-476.	1.1	93
80	The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons. Journal of Biological Chemistry, 2005, 280, 14349-14355.	1.6	92
81	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood, 2012, 119, 476-487.	0.6	91
82	Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis. Nucleic Acids Research, 2017, 45, 4564-4576.	6.5	91
83	Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes. Journal of Biological Chemistry, 2012, 287, 4198-4210.	1.6	89
84	Somatic Mosaic Mutations inPPM1DandTP53in the Blood of Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 370.	3.4	88
85	Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. Journal of Virology, 2016, 90, 4032-4048.	1.5	85
86	Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-Î²-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. Clinical Cancer Research, 2005, 11, 8403-8412.	3.2	84
87	A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines. Experimental Cell Research, 2001, 270, 277-288.	1.2	81
88	Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance. Cancer Research, 2013, 73, 6998-7008.	0.4	81
89	Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cellsâ˜†â˜†â˜†. Gastroenterology, 1998, 114, 930-939.	0.6	80
90	Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells. Journal of Biological Chemistry, 2011, 286, 17682-17692.	1.6	80

#	Article	IF	Citations
91	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. Clinical Cancer Research, 2017, 23, 4077-4085.	3.2	80
92	Comparison of Paclitaxel-, 5-Fluoro-2â€²-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. Journal of Biological Chemistry, 1999, 274, 15927-15936.	1.6	79
93	Apoptosis and the response to anticancer therapy. Current Opinion in Oncology, 2001, 13, 453-462.	1.1	79
94	Is TRAIL hepatotoxic?. Hepatology, 2001, 34, 3-6.	3.6	77
95	Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors: Figure 1.. Genes and Development, 2012, 26, 305-311.	2.7	77
96	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood, 2006, 107, 2501-2506.	0.6	76
97	Apoptosis-associated caspase activation assays. Methods, 2008, 44, 262-272.	1.9	76
98	Phorbol 12-myristate 13-Acetate Inhibits Death Receptor-mediated Apoptosis in Jurkat Cells by Disrupting Recruitment of Fas-associated Polypeptide with Death Domain. Journal of Biological Chemistry, 2002, 277, 3776-3783.	1.6	72
99	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. Blood, 1997, 90, 935-943.	0.6	72
100	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Research, 2002, 62, 6500-5.	0.4	72
101	Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Current Treatment Options in Oncology, 2006, 7, 285-294.	1.3	70
102	Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines. Gastroenterology, 2009, 136, 2365-2376.e7.	0.6	68
103	FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nature Communications, 2020, 11, 1318.	5.8	67
104	Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemotherapy and Pharmacology, 1998, 42, 391-399.	1.1	66
105	Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood, 2003, 102, 4512-4519.	0.6	66
106	Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points. Clinical Cancer Research, 2005, 11, 5935-5941.	3.2	65
107	Apoptosis in the treatment of cancer: a promise kept?. Current Opinion in Cell Biology, 2006, 18, 668-676.	2.6	65
108	Evaluation of the BH3-only Protein Puma as a Direct Bak Activator. Journal of Biological Chemistry, 2014, 289, 89-99.	1.6	65

#	Article	IF	Citations
109	Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 804-815.	1.6	64
110	How does doxorubicin work?. ELife, 2012, 1, e00387.	2.8	64
111	Characterization of Caspase Processing and Activation in HL-60 Cell Cytosol Under Cell-free Conditions. Journal of Biological Chemistry, 1999, 274, 22635-22645.	1.6	63
112	Reutilization of Immunoblots after Chemiluminescent Detection. Analytical Biochemistry, 2001, 296, 283-286.	1.1	62
113	Analysis of the internal nuclear matrix. Experimental Cell Research, 1986, 164, 139-153.	1.2	61
114	Alteration of the Nucleolar Localization of Poly(ADP-ribose) Polymerase upon Treatment with Transcription Inhibitors. Experimental Cell Research, 1996, 227, 146-153.	1.2	61
115	Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel. Clinical Cancer Research, 2004, 10, 6807-6820.	3.2	61
116	CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak. Journal of Biological Chemistry, 2013, 288, 22899-22914.	1.6	59
117	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2016, 22, 4746-4755.	3.2	59
118	Association of topoisomerase II with the hepatoma cell nuclear matrix: The role of intermolecular disulfide bond formation. Experimental Cell Research, 1991, 192, 511-523.	1.2	57
119	Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin. Leukemia and Lymphoma, 2004, 45, 1545-1551.	0.6	57
120	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene, 2005, 24, 5089-5100.	2.6	57
121	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology, 2016, 143, 379-388.	0.6	57
122	Association of poly(ADP-ribose) polymerase with the nuclear matrix: The role intermolecular disulfide bond formation, RNA retention, and cell type. Experimental Cell Research, 1991, 192, 524-535.	1.2	56
123	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 697-706.	3.2	56
124	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	0.6	56
125	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood, 2000, 96, 3922-3931.	0.6	54
126	Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood, 2009, 113, 4841-4852.	0.6	54

#	Article	IF	Citations
127	Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. Journal of Virology, 2017, 91, .	1.5	54
128	Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro. Cancer Research, 2009, 69, 7635-7643.	0.4	53
129	Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro. Clinical Cancer Research, 2012, 18, 5364-5373.	3.2	53
130	Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro. Journal of Biological Chemistry, 2003, 278, 47326-47339.	1.6	52
131	Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells. Blood, 1997, 89, 2098-2104.	0.6	51
132	Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. , 1997, 71, 817-824.		50
133	Detection of DNA Cleavage in Apoptotic Cells. Methods in Enzymology, 2000, 322, 3-15.	0.4	50
134	Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals, 2010, 3, 1311-1334.	1.7	50
135	4EBP1/c-MYC/PUMA and NF-Î²B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood, 2016, 127, 2711-2722.	0.6	49
136	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	0.6	49
137	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. Blood, 1998, 92, 3042-3049.	0.6	48
138	Detection of Poly(ADP-Ribose) Polymerase and Its Apoptosis-Specific Fragment by a Nonisotopic Activityâ€“Western Blot Technique. Analytical Biochemistry, 1995, 232, 251-254.	1.1	47
139	Genomic Mechanisms of p210BCR-ABL Signaling. Journal of Biological Chemistry, 2004, 279, 35604-35615.	1.6	47
140	Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis. Journal of Biological Chemistry, 2009, 284, 18311-18322.	1.6	47
141	Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression. Journal of Biological Chemistry, 2014, 289, 20543-20558.	1.6	47
142	Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis. Journal of Biological Chemistry, 2014, 289, 22835-22849.	1.6	47
143	TP53mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Research, 2015, 43, 6945-6958.	6.5	46
144	Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metabolism, 2018, 28, 833-847.e8.	7.2	46

#	Article	IF	Citations
145	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research, 2020, 26, 3397-3407.	3.2	45
146	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	5.8	44
147	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	3.4	44
148	Methods Utilized in the Study of Apoptosis. Advances in Pharmacology, 1997, 41, 57-87.	1.2	43
149	A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical Cancer Research, 2018, 24, 744-752.	3.2	43
150	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
151	Is TRAIL hepatotoxic?. Hepatology, 2001, 34, 3-6.	3.6	43
152	Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells. Cancer Research, 2011, 71, 4944-4954.	0.4	42
153	Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Research, 2016, 44, 2816-2826.	6.5	42
154	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.4	42
155	Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Research, 2019, 8, 1704.	0.8	42
156	Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Scientific Reports, 2012, 2, 257.	1.6	41
157	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research, 2017, 61, 108-116.	0.4	41
158	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood, 2005, 105, 2099-2106.	0.6	40
159	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research, 2019, 79, 5920-5929.	0.4	40
160	Genes associated with bowel metastases in ovarian cancer. Gynecologic Oncology, 2019, 154, 495-504.	0.6	40
161	A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical Cancer Research, 2003, 9, 2520-6.	3.2	40
162	Caspase-7 Gene Disruption Reveals an Involvement of the Enzyme during the Early Stages of Apoptosis. Journal of Biological Chemistry, 2004, 279, 1030-1039.	1.6	38

#	Article	IF	Citations
163	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 2008, 7, 2339-2347.	1.9	38
164	Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes and Development, 2015, 29, 2140-2152.	2.7	38
165	S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells. BioTechniques, 2004, 37, 835-9.	0.8	38
166	Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death. Journal of Biological Chemistry, 2004, 279, 18641-18647.	1.6	37
167	Mcl-1 Degradation during Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2009, 284, 30039-30048.	1.6	37
168	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica, 2011, 96, 1619-1626.	1.7	37
169	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, 118, 4882-4889.	0.6	37
170	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2017, 23, 899-907.	3.2	37
171	Irinotecan in the treatment of glioma patients. Cancer, 2003, 97, 2352-2358.	2.0	36
172	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochemical Pharmacology, 2018, 152, 279-292.	2.0	35
173	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
174	Mitochondrial apoptosis and BH3 mimetics. F1000Research, 2016, 5, 2804.	0.8	33
175	Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer. Cancer Research, 2020, 80, 857-867.	0.4	33
176	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	2.7	33
177	Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemotherapy and Pharmacology, 1994, 34, S53-S57.	1.1	32
178	Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside. Mayo Clinic Proceedings, 2002, 77, 760-762.	1.4	32
179	Osteoblasts Protect AML Cells From SDFâ€1â€Induced Apoptosis. Journal of Cellular Biochemistry, 2014, 115, 1128-1137.	1.2	32
180	Characterization of an alternative BAK-binding site for BH3 peptides. Nature Communications, 2020, 11, 3301.	5.8	31

#	Article	IF	Citations
181	Proteolytic cleavage during chemotherapy-induced apoptosis. Trends in Molecular Medicine, 1996, 2, 298-303.	2.6	30
182	Comparison of complication rates of Hickman^{Â®}catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leukemia and Lymphoma, 2013, 54, 1263-1267.	0.6	29
183	A One-Step Method for Protein Estimation in Biological Samples: Nitration of Tyrosine in Nitric Acid. Analytical Biochemistry, 1999, 267, 217-221.	1.1	28
184	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. Journal of Cell Biology, 2014, 206, 867-876.	2.3	28
185	Binding of dexamethasone to rat liver nuclei in vivo and in vitro: Evidence for two distinct binding sites. The Journal of Steroid Biochemistry, 1984, 20, 699-708.	1.3	27
186	High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling*. Journal of Biological Chemistry, 2011, 286, 35823-35833.	1.6	27
187	Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood, 2011, 118, 4872-4881.	0.6	27
188	Measurement of BH3-only protein tolerance. Cell Death and Differentiation, 2018, 25, 282-293.	5.0	27
189	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. Blood, 1997, 90, 4283-4296.	0.6	27
190	Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia. Clinical Cancer Research, 2005, 11, 6641-6649.	3.2	26
191	Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica, 2014, 99, 60-69.	1.7	26
192	Auxin-induced Rapid Degradation of Inhibitor of Caspase-activated DNase (ICAD) Induces Apoptotic DNA Fragmentation, Caspase Activation, and Cell Death. Journal of Biological Chemistry, 2014, 289, 31617-31623.	1.6	26
193	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. , 2021, 4, 125-142.		26
194	Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. Cancer Research, 2022, 82, 1038-1054.	0.4	26
195	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine, 2021, 2, 100471.	3.3	26
196	Therapyâ€related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*. European Journal of Haematology, 2012, 88, 237-243.	1.1	25
197	Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2. PLoS Pathogens, 2020, 16, e1008906.	2.1	25
198	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. Journal of Clinical Oncology, 2016, 34, 5540-5540.	0.8	25

#	Article	IF	Citations
199	Effect of 6-Aminonicotinamide and Other Protein Synthesis Inhibitors on Formation of Platinum-DNA Adducts and Cisplatin Sensitivity. Molecular Pharmacology, 2000, 57, 529-538.	1.0	24
200	Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. Journal of Clinical Investigation, 2009, 119, 2714-24.	3.9	24
201	Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochemical Pharmacology, 1999, 58, 1057-1066.	2.0	23
202	Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines. Molecular Pharmacology, 2003, 64, 1434-1443.	1.0	23
203	Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Molecular Cancer Therapeutics, 2009, 8, 855-863.	1.9	23
204	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2012, 119, 55-63.	0.6	23
205	A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecologic Oncology, 2012, 124, 210-215.	0.6	23
206	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clinical Cancer Research, 2016, 22, 3894-3902.	3.2	23
207	TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 162-185.	2.6	22
208	Increased phosphorylation rate of intermediate filaments during mitotic arrest. Experimental Cell Research, 1981, 133, 445-449.	1.2	21
209	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications, 2019, 10, 4632.	5.8	21
210	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	2.0	21
211	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
212	Topoisomerase II and the Response to Antileukemic Therapy. Leukemia and Lymphoma, 1998, 29, 217-237.	0.6	20
213	Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	1.6	20
214	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 490-497.	0.6	20
215	Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388â€“granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Blood, 2001, 98, 1927-1934.	0.6	19
216	Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs, 2013, 31, 1201-1206.	1.2	19

#	Article	IF	Citations
217	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	1.7	19
218	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 67, 455-463.	1.1	18
219	Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1Î±-TAZ Signaling Pathway in Osteoblasts. Journal of Biological Chemistry, 2015, 290, 29478-29492.	1.6	18
220	Anticancer therapy: boosting the bang of Bim. Journal of Clinical Investigation, 2008, 118, 3582-3584.	3.9	18
221	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. Journal of Hepatology, 2018, 68, 1228-1238.	1.8	17
222	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor Î±. Clinical Cancer Research, 2020, 26, 2986-2996.	3.2	17
223	Immunoblot Analysis and Band Depletion Assays. , 1999, 94, 253-268.		16
224	Isolation of a TRAIL Antagonist from the Serum of HIV-infected Patients*. Journal of Biological Chemistry, 2011, 286, 35742-35754.	1.6	16
225	An Alternative Approach to the Quantitation of Glucocorticoid-Receptor Complexes in the Nuclei of Lymphoid Cells*. Endocrinology, 1982, 110, 708-716.	1.4	15
226	Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I. Journal of Biological Chemistry, 2008, 283, 16711-16722.	1.6	15
227	Protein Kinase CÎ² Modulates Ligand-induced Cell Surface Death Receptor Accumulation. Journal of Biological Chemistry, 2010, 285, 888-902.	1.6	15
228	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology, 2022, 164, 245-253.	0.6	15
229	Addition of Etoposide to Initial Therapy of Adult Acute Lymphoblastic Leukemia: A Combined Clinicaland Laboratory Study. Leukemia and Lymphoma, 1996, 23, 71-83.	0.6	14
230	Hypercalcemia Complicating Leukemic Transformation of Agnogenic Myeloid Metaplasia-Myelofibrosis. Mayo Clinic Proceedings, 1999, 74, 1233-1237.	1.4	13
231	On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4459-4462.	1.0	13
232	Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. International Journal of Cancer, 2014, 135, 1783-1789.	2.3	13
233	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. Blood, 1998, 92, 3042-3049.	0.6	13
234	Genetic Analysis of the Short Splice Variant of the Inhibitor of Caspase-activated DNase (ICAD-S) in Chicken DT40 Cells. Journal of Biological Chemistry, 2007, 282, 27374-27382.	1.6	12

#	Article	IF	Citations
235	Erasure of Western Blots After Autoradiographic or Chemiluminescent Detection. Methods in Molecular Biology, 1998, 80, 223-235.	0.4	12
236	Factors Affecting Topotecan Sensitivity in Human Leukemia Samples. Annals of the New York Academy of Sciences, 1996, 803, 128-142.	1.8	11
237	Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidine (SCH66336). Molecular Pharmacology, 2005, 68, 477-486.	1.0	11
238	Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association. Blood, 2010, 116, 772-772.	0.6	11
239	A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer. Cancer Investigation, 2011, 29, 617-625.	0.6	10
240	USP13 regulates the replication stress response by deubiquitinating TopBP1. DNA Repair, 2021, 100, 103063.	1.3	10
241	Synthesis of Novel Caspase Inhibitors for Characterization of the Active Caspase Proteome in Vitro and in Vivo. Journal of Medicinal Chemistry, 2006, 49, 7636-7645.	2.9	9
242	Imatinib spells BAD news for Bcr/abl-positive leukemias. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14651-14652.	3.3	9
243	Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific Reports, 2019, 9, 3617.	1.6	9
244	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Scientific Reports, 2021, 11, 8076.	1.6	9
245	The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. Genes, 2021, 12, 1098.	1.0	9
246	Uncovering Pharmacological Opportunities for Cancer Stem Cellsâ€"A Systems Biology View. Frontiers in Cell and Developmental Biology, 2022, 10, 752326.	1.8	9
247	Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistancein vitro. Investigational New Drugs, 1995, 13, 285-294.	1.2	8
248	Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. Molecular and Cellular Biochemistry, 1998, 178, 245-249.	1.4	8
249	Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines. Molecular Pharmacology, 2008, 74, 724-735.	1.0	8
250	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€“ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	1.2	8
251	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. Journal of Clinical Oncology, 2014, 32, TPS5619-TPS5619.	0.8	8
252	MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia. Blood, 2015, 126, 1273-1273.	0.6	8

#	Article	IF	Citations
253	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2022, 82, 307-319.	0.4	8
254	Analysis of Caspase Activation During Apoptosis. Current Protocols in Cell Biology, 2001, 11, Unit 18.2.	2.3	7
255	Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. Hepatology Research, 2010, 40, 701-710.	1.8	7
256	Porphyromonas somerae Invasion of Endometrial Cancer Cells. Frontiers in Microbiology, 2021, 12, 674835.	1.5	7
257	PARP inhibitor maintenance for primary ovarian cancer â€“ A missed opportunity for precision medicine. Gynecologic Oncology, 2021, 163, 11-13.	0.6	7
258	Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochemical Pharmacology, 1995, 50, 1987-1993.	2.0	6
259	Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons. Molecular Pharmacology, 2014, 85, 723-734.	1.0	6
260	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
261	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. Blood, 2004, 104, 129-129.	0.6	6
262	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. Blood, 2006, 108, 530-530.	0.6	6
263	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,. Blood, 2011, 118, 3634-3634.	0.6	6
264	A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Investigational New Drugs, 2002, 20, 297-304.	1.2	5
265	Apoptosis: an optimization approach. Computers in Biology and Medicine, 2004, 34, 449-459.	3.9	5
266	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem Cells Translational Medicine, 2017, 6, 840-850.	1.6	5
267	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 307-314.	1.2	5
268	CDK2-Mediated Upregulation of TNFÎ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research, 2021, 81, 2666-2678.	0.4	5
269	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. Journal of Physical Education and Sports Management, 2021, 7, a006083.	0.5	5
270	Manifold medicine: A schema that expands treatment dimensionality. Drug Discovery Today, 2022, 27, 8-16.	3.2	5

#	Article	IF	Citations
271	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	0.6	5
272	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. Blood, 2011, 118, 400-400.	0.6	5
273	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood, 2000, 96, 3922-3931.	0.6	5
274	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 721-735.	1.1	5
275	Dynamics of granzyme B-induced apoptosis: Mathematical modeling. Mathematical Biosciences, 2008, 212, 54-68.	0.9	4
276	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget, 2017, 8, 94569-94579.	0.8	4
277	Circulating CD14 + HLAâ€ÐR lo/â˜ monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology, 2021, 85, e13343.	1.2	4
278	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death and Disease, 2021, 12, 789.	2.7	4
279	Gadolinium-enhanced cardiac MR exams of human subjects are associated with significant increases in the DNA repair marker 53BP1, but not the damage marker Î³H2AX. PLoS ONE, 2018, 13, e0190890.	1.1	4
280	Erasable Western Blots. , 1992, 80, 235-246.		3
281	Topoisomerases in Human Leukemia. Advances in Pharmacology, 1994, 29B, 33-50.	1.2	3
282	Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. American Journal of Hematology, 2005, 79, 119-127.	2.0	3
283	The Intrinsic Pathway of Apoptosis. , 2007, , 3-30.		3
284	Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9860-9865.	3.3	3
285	Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. Organic and Biomolecular Chemistry, 2016, 14, 4103-4109.	1.5	3
286	A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML). Blood, 2019, 134, 3837-3837.	0.6	3
287	The Role of Proteases in Neuronal Apoptosis. Frontiers in Neuroscience, 1998, , .	0.0	3
288	Therapeutics targeting BCL2 family proteins. , 2022, , 197-260.		3

#	Article	IF	Citations
289	Erasure of Western blots after autoradiography or chemiluminescent detection. Applied Biochemistry and Biotechnology, 1993, 38, 243-255.	1.4	2
290	Selective Inhibition of BFL1: Itâ€™s All about Finding the Right Partner. Cell Chemical Biology, 2020, 27, 639-642.	2.5	2
291	Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.. Blood, 2004, 104, 2097-2097.	0.6	2
292	Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia. Blood, 2011, 118, 1531-1531.	0.6	2
293	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. Blood, 2015, 126, 2563-2563.	0.6	2
294	Resistance to topoisomerase II poisons: Is the answer in the promoter?. Leukemia Research, 1997, 21, 1033-1036.	0.4	1
295	Reutilization of Western Blots After Chemiluminescent Detection or Autoradiography. , 2002, , 439-452.		1
296	Apoptotic Pathways in Cancer Progression and Treatment. , 0, , 143-170.		1
297	Cell division, growth and death. Current Opinion in Cell Biology, 2005, 17, 565-567.	2.6	1
298	Genetic analysis of apoptotic execution. Sub-Cellular Biochemistry, 2006, 40, 75-90.	1.0	1
299	Altered Apoptosis in AML. , 2007, , 133-161.		1
300	Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition. , 2015, , .		1
301	OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy. Blood, 2010, 116, 970-970.	0.6	1
302	Targeting the Apoptotic Machinery as a Potential Antileukemic Strategy. , 0, , 163-186.		1
303	Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio. Blood, 2012, 120, 1508-1508.	0.6	1
304	Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer. , 2013, , .		1
305	Proteolytic Cleavage of Poly(ADP-Ribose) Polymerase in Human Leukemia Cells Treated with Etoposide and other Cytotoxic Agents. , 1992, , 260-268.		1
306	Methods Used to Study Protease Activation During Apoptosis. Frontiers in Neuroscience, 1998, , .	0.0	1

#	Article	IF	Citations
307	A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML). Blood, 2021, 138, 2347-2347.	0.6	1
308	Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. Translational Oncology, 2022, 21, 101427.	1.7	1
309	Nitric oxide (NO) inhibits apoptosis in cholangiocarcinoma cells by blocking caspase 9 activation. Gastroenterology, 2000, 118, A962.	0.6	0
310	The Nitric Acid Method for Protein Estimation in Biological Samples. , 2002, , 31-40.		0
311	Imatinib mesylate (STI-571), a c-Abl kinase inhibitor, indirectly blocks receptor tyrosine kinase activation and induces apoptosis in a human cholangiocarcinoma cell line. Gastroenterology, 2003, 124, A742.	0.6	0
312	Hopes for kinase inhibitors active against AML take FLT. Blood, 2004, 103, 8-8.	0.6	0
313	The Nitric Acid Method for Protein Estimation in Biological Samples. Springer Protocols, 2009, , 35-45.	0.1	0
314	Reutilization of Western Blots After Chemiluminescent or Autoradiographic Detection. Springer Protocols, 2009, , 789-806.	0.1	0
315	Chk1 and WEE1 Inhibition Combine Synergistically and Represent a Novel Non-cytotoxic Combination in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S127-S128.	0.2	0
316	Approaches Used to Detect Apoptosis. , 2005, , 35-54.		0
317	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. Blood, 2009, 114, 2742-2742.	0.6	0
318	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. Blood, 2010, 116, 3276-3276.	0.6	0
319	Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial. , 2011, , .		0
320	Abstract 4179: Loss of Hsulf-1 promotes chemoresistance and tumorigenecity in ovarian cancer. , 2012, , .		0
321	Abstract 3276: A novel in vivo xenograft mouse model of human high-grade serous ovarian cancer, with clinical, molecular and functional annotation relevant for pre-clinical analysis. , 2012, , .		0
322	Abstract 1737: Pharmacological inhibition of fatty acid synthase regulates BH3-only proteins and sensitizes breast cancer cells to a small molecule Bcl-2/Bcl-xL inhibitor to induce apoptosis.. , 2013, , .		0
323	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	0.6	0
324	Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations. , 2014, , .		0

#	Article	IF	Citations
325	Abstract 38: Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer. , 2014, , .		0
326	mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies. Blood, 2015, 126, 3705-3705.	0.6	0
327	Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.. , 2016, , .		0
328	Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.. , 2016, , .		0
329	Abstract A07: Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas.. , 2016, , .		0
330	Abstract 1260: Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell. , 2016, , .		0
331	Abstract 3292: Manipulating osteoblast differentiation in order to inhibit protection of AML cells within the bone marrow. , 2016, , .		0
332	Getting a GRP on histone deacetylase inhibitor selectivity. Oncotarget, 2017, 8, 78249-78250.	0.8	0
333	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	0.6	0
334	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 2021, 13, 6043.	1.7	0
335	Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation. Blood, 2020, 136, 12-13.	0.6	0
336	Erasure of Western Blots After Autoradiographic or Chemiluminescent Detection. , 0, , 223-236.		0